Fig 1: Dynamic changes of coagulation and thrombosis-related indicators in the two outcomes after the critical illness turned into severe and the critically ill patients eventually died. A.1, A.2 Dynamic changes of IP-10: when the critical illness turned into severe, the IP-10 level in most patients increased at first and then decreased along the 20–30 days of the disease. When the critical illness turned into death, the IP-10 level in most patients decreased at first and then increased in approximately 20–30 days of disease progression. B.1, B.2 Dynamic changes of MCP-1: when the critical illness turned into severe, the MCP-1 level gradually decreased in most patients. When the critical illness turned to death, the MCP-1 level gradually increased in most patients. C.1, C.2 Dynamic changes of MIP1α: when the critical illness turned into severe, the MIP1α level gradually decreased in most patients. When the critical illness turned into death, the MIP1α level gradually increased in most patients
Fig 2: ROC curves of IP-10, MCP-1, d-dimer and combined indicators in blood tests of COVID-19 patients
Fig 3: Comparison of relative expressions of TNF-a, MCP-1, VCAM-1, ICAM-1, and IL-6 in the high risk, moderate risk, and low risk groups.
Fig 4: i-PCSK9 ameliorated the ability of i-miR-15b against LPS-related inflammation. A Hsa-miR-15b-5p levels and B immunoblotting of SIRT4. Mean ± SD, n = 3. M, molecular weight markers; lane 1, Ctr; lane 2, LPS; lane 3, i-PCSK9; lane 4, i-PCSK9 + LPS. Detection of C ICAM1, D VCAM1, E MCP-1, F IL-1ß, and G IL-18. Mean ± SD, n = 3. ‡p < 0.01 versus Ctr or NC, ¶p < 0.001 versus Ctr, §p < 0.001 versus NC, •p < 0.05 versus LPS or NC + LPS, †p < 0.01 versus NC + LPS, °p < 0.05 versus i-miR-15b + LPS. Statistical analysis of data was performed using one-way ANOVAs.
Fig 5: Spearman correlation analysis of KIM-1 (A), NGAL (B), MCP-1 (C), ß2M (D), and MoCA scores.
Supplier Page from Abcam for Human MCP-1 ELISA Kit